PetVivo Holdings Reports Revenue Growth to $303,284 but Faces $3M Net Loss

PetVivo Holdings, Inc. reported its financial results for the quarter ending September 30, 2025, revealing a revenue increase to $303,284, up from $200,720 in the same period last year. The company attributed this growth primarily to the introduction of its new product, PrecisePRP™, which generated $116,382 in sales. In contrast, sales from the existing product, Spryng®, accounted for $186,902 during the quarter. Despite the revenue growth, PetVivo recorded a net loss of $3,007,809, consistent with the loss of $2,175,493 reported in the prior year, resulting in a loss per share of $0.11.

The company’s total operating expenses for the quarter were $2,285,425, a slight decrease from $2,352,598 in the previous year. This reduction was primarily due to lower general and administrative expenses and research and development costs, which fell to $261,433 from $465,174 year-over-year. The decrease in R&D spending was attributed to cash flow constraints affecting clinical studies. The overall operating loss for the quarter was $2,065,367, compared to $2,173,040 in the same quarter last year.

In terms of strategic developments, PetVivo has made significant strides in expanding its product offerings and market presence. The company signed an exclusive licensing agreement with VetStem, Inc. in February 2025 to market and sell PrecisePRP™, a product designed for intra-articular administration in dogs and horses. This agreement is expected to enhance PetVivo's market position in the veterinary medical device sector. Additionally, the company has entered into distribution agreements with MWI Veterinary Supply Co. and Vedco, Inc., which are aimed at increasing the reach of its products in the veterinary market.

Operationally, PetVivo's total current assets as of September 30, 2025, were reported at $2,109,723, with cash and cash equivalents amounting to $767,914. The company’s current liabilities stood at $1,052,694, resulting in a working capital of $1,057,029. The company has also seen an increase in its employee headcount, which is indicative of its growth strategy. However, the company continues to face challenges, including an accumulated deficit of $96,670,939, raising concerns about its ability to sustain operations without additional capital.

Looking ahead, PetVivo Holdings, Inc. acknowledges the need for further capital to support its ongoing operations and product commercialization efforts. The company plans to continue raising funds through the sale of securities to finance its business expansion. Management remains optimistic about the potential for revenue growth from its new product lines, but recognizes the inherent risks and uncertainties in achieving profitability. The company’s ability to continue as a going concern will depend on its success in executing its business plan and securing necessary financing.